Ca 15-3 is an aspecific tumor marker characteristic of cancer proliferation. Elevated serum levels seem to be closely correlated with cancer progression in non-urological tumors. This study assessed the role of Ca 15-3 as an aspecific tumor marker in patients with borderline prostate-specific antigen (PSA) biochemically suspected of prostate cancer (PCa) and with multiple negative prostate biopsies.
Introduction
The definition of tumor markers formulated by Luthgens 1 is accepted worldwide and includes all substances that are synthesized by tumor cells and secreted by them that can be determined and quantified by noninvasive techniques. The malignant cell must transform into a tumor before these substances increase. Thus, tumor markers are potentially pathognomonic biomarkers at early stages of cancer and are useful in early diagnosis. Ideal tumor markers should present: (i) absolute sensitivity correlatable with active tumor cell proliferation associated with quantifiable elevated secretion of proliferating substances in organic liquids even in the presence of neoplastic microaggregates; (ii) marked organ specificity in order to identify the tumor focus and make diagnosis. However, at present, these essential requisites are only possessed by specific markers presenting limited sensitivity, which is crucial for early diagnosis, and organ specificity.
At present prostate-specific antigen (PSA) is the universally accepted tumor marker in prostate cancer, prostate diagnosis and monitoring. It is a glycoprotein that exists in various molecular forms and detection of its serum values (normal values: 0 -4 ng/ml) has revolutionized the clinical history of prostate cancer as it allows early diagnosis and radical oncologic treatment. PSA is a functional product secreted by normal prostatic epithelium and required for lysing seminal coagulum, and its concentrations in prostatic fluid are about 1 million-fold above serum values. The intraductal quota of PSA is structurally separated from prostatic capillary and lymphatic drainage by a triple layer (epithelial cells, basal cells, BM). Therefore, PSA possesses marked specificity and diagnostic efficacy (90 -92%), accompanied by low sensitivity (54 -56%). It is known that 21 -47% of men affected by BHP 2 have PSA values > 4 ng/ml and that 38 -48% of organ confined tumors 3 present normal values. Low PSA concentrations can be associated with tumors in the bone metastatic stage (0.5 -2%), 4 while only 28.5 -37% of patients with PSA > 4 ng/ml do not have palpable prostate cancer. 5 Other benign diseases (urine retention, prostatitis, prostatic infarction) and simple procedures (digital-rectal examination (DRE), transrectal ultrasound (TRUS) and prostate biopsy) can raise serum PSA concentrations. 6, 7 Because of the above-mentioned limitations of serum PSA determinations, the use of alternative easily detectable low-cost serum markers has become mandatory in diagnosing early cancer in cases where clinically, instrumentally and biochemically suspected cancer is not supported by histologic findings.
We decided to assess another marker of tumor proliferation and progression alongside PSA. We selected Ca 15-3, a mucin-like epithelial polypeptide with high molecular weight (300 -450 kDa) that can be determined by IRMA method.
Ca 15-3 is one of the tumor markers that were initially considered specific solely for some types of tumors, but were soon found to be indicative of different types of tumors, albeit at different concentrations. It is a clear example of a tumor marker possessing elevated sensitivity associated with modest specificity, therefore its increase could also represent an alarm bell for PCa in the presence of increased serum PSA values.
Ca 15-3 (or carbohydrate antigen 15-3) was initially identified as an expression of breast cancer cell proliferation, towards which it possesses about 15% specificity depending on the disease stage, although its overall specificity of the entire course of the disease is about 80%. It was subsequently identified in other tumors of different tissues, such as lung, bowel, ovary and prostate. 8, 9 .
Up until now in prostate carcinoma the analyzed results have been summary and discordant, primarily in relation to the non-homogeneity of recruited patients in the performed studies, and have prevented definitive conclusions being drawn as to Ca 15-3 in PCa. 10, 11 Peripheral serum Ca 15-3 values are easily determined by immunoradiometric method and costs are comparable to serum PSA determination. In the literature, data on inherent different non-urological tumors confirm that the maximum Ca 15-3 value in the normal range is 38 UI/l (IRMS BR-MA kit, EURO/DPC Ltd) and any slight rise above this threshold can be considered a sign of tumor proliferation.
Tumor tissue expression of Ca 15-3 and other mucinlike markers, such as MCA, Ca 19-9, Ca 195, Ca 72.4, Ca 50, Ca 549 and Ca 125, is the codifying gene for PEM or MUC-1 surface polymorphic epithelial mucin expressed by tumor cells deriving from epithelial cells. 12 The MUC-1 codifying gene, whose expression seems to be partially regulated by steroid hormones, is located on the short arm of chromosome 1 (1q25) and is expressed on normal cell surface as an integral membrane glycoprotein with a rod-like tridimensional structure weighing about 200 kDa. The various remodelling processes of the MUC-1 gene can originate as many as 10 different types of mucin. Even if the glycoamino acid chains of these types differ in size, all of the types are involved in balancing cell growth. MUC-1 maintains cell homeostasis by regulating intercellular interaction, cytoskeletal structure differentiation, caderine, catenine and integrine activity and by stimulating lymphocyte T-mediated differentiation and activation of the immune response. Altered molecule expression induced by various oncogenic factors reduces glycosilation and increases the number of MUC-1 molecules on the cell surface. This, in turn, leads to deregulation of the mechanisms of oncogenic cytoprotection and consequent transformation into tumor of the cell strain involved. Therefore, it seems evident that altered MUC-1 expression on the surface of cells that have differentiated into tumors raises Ca 15-3 concentrations, an epithelial mucin detectable in serum that reveals neoplastic proliferation and onset of cancer despite the limitations of the marker's reduced oncospecificity. In relation to the evident correlation between MUC-1 expression and Ca 15-3, there are possible false positive results, especially in infections responsible of epithelial modifications. 13, 14 
Materials and methods
The study aim was to assess whether the tumor marker Ca 15-3 could facilitate diagnosis of prostate adenocarcinoma that are biochemically suspected from increased serum PSA values, but not histologically confirmed. Therefore we assessed, through a prospective analysis, the potential diagnostic efficacy of Ca 15-3 in terms of sensitivity, as an aspecific marker of tumor proliferation, in patients with borderline PSA concentrations, biochemically suspected for PCa, but negative DRE and TRUS findings, PSA ratio (free/total) < 15%, PSA density (PSA/prostate volume) > 0.15 and multiple negative ( 2) ecoguided transrectal prostate biopsies.
We investigated 103 male patients, aged between 59 and 88 y (mean age 69.4 y). The following examinations were performed in all the series: DRE, TRUS, total serum PSA and PSA ratio determination (free/total PSA ratio in patients with borderline PSA), PSA density (ratio between PSA expressed in ng/ml and prostate volume expressed in cm 3 ). The patients were divided into three groups as follows (Table 2 ). Group A consisted of 33 patients with lower urinary tract symptoms (LUTS) induced by BPH (UFM with peak flow between 8.9 and 12.8 ml/s). DRE and TRUS findings were negative for tumor lesions. PSA values were between 1.3 and 3.4 ng/ml and PSA density ranged between 0.04 and 0.09. Group B was made up of 31 patients where the first biopsy had histologically diagnosed prostate adenocarcinoma and Gleason score between 3 and 8. Of these 19 patients in clinical stage T2a-b N0 M0, six patients were in stage T3a Nþ M0, and six patients were in T3b-T4 Nþ Mþ. DRE had revealed tumor lesions in 90.32% of the cases with hard monolateral node in 16 patients, bilateral nodes in five patients and entirely hard prostate and non-definable margins in seven patients. TRUS had been positive and revealed hypoechogeneous nodular areas in 77.42% (24 patients) and isohyperechogeneous in the remaining 22.58% (seven patients). PSA values ranged between 18.5 and 114.7 ng/ ml and corresponded directly with tumor staging determined by abdominal and pelvic CT, bone scan and chest X-ray.
Group C was made up of 39 LUTS-free patients who had come to our attention because of increased serum PSA concentrations (range 6.3 -12.6 ng/ml) and decreased PSA ratio (11 -15%). DRE and TRUS had not revealed tumor lesions and PSA density was between 0.28 and 0.44. Two random ecoguided prostatic biopsies (sextant technique) had been performed in each patient but had been histologically negative for prostate cancer.
Two peripheral blood samples were withdrawn from all 103 patients within 24 hours to determine serum Ca 15-3 concentrations. PSA was determined using IRMAmat kit (Byk-Sangtec Diagnostica GmbH & Co. KG, Dietzenbach, Germany). PSA values below 4.0 ng/ml were considered normal.
The dosage of Ca 15-3 is performed with IRMA-Count BR-MA (EURO/DPC Ltd), an immunoradiometric assay based on ligand-coated tubes and two liquid monoclonal anti-Ca 15-3 antibodies, one 125I-labeled, the other ligand-labeled. Ca 15-3 in the patient sample is captured between the monoclonal, in a reaction proceding with liquid-phase kinetics. Separation is then achieved by the ligand-coated tube/anti-ligand bridge method. Counting the tube in a gamma counter yields a number that converts by way of calibration curve to a measure of the Ca 15-3 present in the patient sample.
Ca 15-3 concentrations were expressed in U/l and values under 38 U/l were considered normal. This cutoff was selected in agreement with the literature for nonurological tumors and the specific kit utilized, and is the expression of a careful analysis of control patients in whom malignant tumors had been ruled out or detected.
Results
Serum Ca 15-3 concentrations varied in the three study groups and were partly correlated with total PSA values, and only slightly influenced by PSA ratio and PSA density. All the group A control patients (n ¼ 33), with normal PSA range affected by LUTS associated with BHP, had normal Ca 15-3 values between 8.9 and 13.7 U/l (Table 3) . A three-fold increment in Ca 15-3 concentrations (76.4 -83.1 U/l) was observed in 27/31 (87.1%) group B patients (subgroup B1), with histologically diagnosed PCa after only one biopsy, while the remaining four patients (12.9%) had normal serum concentrations (24.1 -36.2 U/l, subgroup B2; Table 3 ). It is noteworthy that these four patients had poorly differentiated prostatic adenocarcinoma (Gleason score 8) and extra spread with bone metastases (T3b-T4 Nþ Mþ). Moreover, after 3 months of hormone therapy maximal androgen blockade serum PSA values in three of four of these subjects was reduced by 13 -26% compared with pretreatment levels, with no changes in detectable Ca 15-3. The latter finding may be ascribable to marked tumor cell undifferentiation without carbohydrate antigen expression on the cell surface (cell anaplasia with molecule synthetic block). Group C patients (n ¼ 39), presenting biochemically suspected PCa (total PSA values 6.3 -12.6 ng/ml), without clinical or instrumental signs of heteroplastic lesions, in relation to Ca 15-3 value were divided into two subgroups, C1 (28 patients) and C2 (11 patients). Ca 15-3 values were within the normal range (19.1 -33.2 U/l) in subgroup C1 (71.8%) and elevated (41.4 -59.6 U/l) in subgroup C2 (28.2%, Table 3 ). (11) 41.4 -59.6
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All 39 group C patients with borderline PSA values, where two sextant guided transrectal prostatic biopsies had been histologically negative for cancer, underwent a third biopsy that was positive in 13 patients (33.3%), identified as subgroup C3 (third positive biopsy).
In this series, nine of 13 patients (69.2%, subgroup C3a) presented elevated serum Ca 15-3 concentrations (54.9 -59.6 U/l), associated with organ-confined disease and intermediate differentiation grade (Gleason score 5 -7). Instead, Ca 15-3 levels were within the lower limits of the normal range (22.4 -25.8 U/l) in the remaining four of 13 patients (30.8%, subgroup C3b), presenting well-differentiated tumors (Gleason score 2 -4) and intraorgan spread ( Table 4) .
The third biopsy was negative for prostate cancer in the other 26 group C patients, identified as subgroup C4 (66.7%, third negative biopsy). In this study group, 24 of 26 patients (92.3%, subgroup C4a) presented normal Ca 15-3 values (2.19 -23.4 U/l) with histologic findings of fibromyoadenomatous hyperplasia (BPH) in 23 cases and chronic prostatitis with lymphoplasmacytic infiltrates and granulomatous foci in just one case. The remaining 2/26 patients (7.7%, subgroup C4b) presented elevated Ca 15-3 concentrations (52.8 -54.4 U/l) associated with histologic findings of chronic prostatitis with lymphoplasmacytic infiltrates (Table 5 ). Abdominal and pelvic CT, bone scan and chest X ray were performed in these patients for cancer staging and to exclude other concomitant tumors.
Discussion and conclusions
Our results would indicate that Ca 15-3 could be an interesting tool in diagnosing patients with biochemically suspected prostate cancer, related to increased serum PSA concentrations, but without DRE and TRUS findings of cancer. Thus, Ca 15-3 determination could be proposed as an aspecific tumor marker to decide whether to perform short-term additional biopsies in patients with PSA borderline, PSA ratio (F/T) < 15% and/or PSA density > 0.15, when repeated echoguided trans-rectal biopsies (two) were negative for prostate cancer.
The high bioptic detection rate, equal to 33.3% of group C patients (13 of 39 patients), would not influence the final statements, even if two biopsies could be considered an insufficient number of histological evaluations to be a source of bias. We considered these results exclusively as preliminary findings on the applicability of an alternative tumor marker in suspected PCa patients, in which an additional biopsy usually represents a procedure that is poorly accepted by the patient. However the limits of the diagnostic sensitivity of the marker in patients with PCa, valuedup until now in a relatively small number of cases, are evident and they would seem to correlate especially with the Gleason score.
The results revealed that Ca 15-3 values were within the normal range in well differentiated tumors (Gleason score 2 -4) and in greatly undifferentiated ones with marked cell anaplasia (Gleason score 8). In both types of tumors, well and poorly differentiated, there may be Ca 15-3 hypo-expression on the tumor cell surface.
Hypothetically, this hypoexpression could be attributed to relative inhibition of the codifying gene for Ca-15-3 by an oncosuppressor gene activated specifically in well differentiated tumors and in cells with marked anaplasia, where the cellular components are no longer under the control of proliferative and apoptotic processes. However, the antigen hypexpression in moderately differentiated tumors (Gleason score 5 -7) could be induced by a complete oncosuppressor gene inhibition with consequent gene deregulation and increased molecular synthesis.
Therefore, Ca 15-3 determination would furnish reliable diagnostic findings primarily in intermediate grade tumors (Gleason score 5 -7), where mucin synthetic regulation is intact with consequent antigenic expression on tumor cell membrane and elevated Ca 15-3 serum concentrations. Thus, it does not mean that the marker is specific for PCa, rather its expression is limited to a small Figure 1 Subgroups C related to third biopsy positivity.
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In conclusion, our study reveals that determination of Ca 15-3 is a potentially helpful, low cost method that could flank PSA determination as an aspecific tumor marker in prospective long-term studies of patients with biochemically suspected prostate cancer. Besides, as Ca 15-3 is also present in males in other forms of cancer (lung and bowel cancer), and specific diagnostic investigations in the presence and absence of prostate cancer should be performed to rule out these diseases when Ca 15-3 values are increased.
